Heat shock proteins (hsp), hsp60 and hsp10, are involved in the folding of imported mitochondrial proteins and the refolding of denatured proteins after stress. We examined whether hsp10 can reduce myocyte death by its mitochondrial function or by interacting with cytoplasmic signaling pathways. Overexpression of hsp10 by adenoviral infection decreased myocyte death induced by hydrogen peroxide, sodium cyanide, and simulated ischemia and reoxygenation (SI/RO). We generated an adenoviral vector coding for a temperature-sensitive mutant hsp10 protein (P34H), incapable of cooperatively refolding denatured malate dehydrogenase with hsp60. Overexpression of the hsp10 mutant potentiated SI/RO-induced myocyte death. Analysis of electron transport chain function revealed increased Complex I capacity with hsp10 overexpression, whereas hsp10(P34H) overexpression decreased Complex II capacity. Hsp10 overexpression preserved both Complex I and II function after SI/RO. Examination of the Ras GTP-ase signaling pathway indicated that inhibition of Ras was required for protection by hsp10. Constitutive activation of Ras abolished the effects afforded by hsp10 and hsp10(P34H). Hsp10 overexpression inactivated Raf, ERK, and p90Ribosomal kinase (p90RSK) before and after SI/RO. Our results suggest that complex mechanisms are involved in the protection by hsp10 against SI/RO-induced myocyte death. This mechanism may involve the hsp10 mobile loop and attenuation of the Ras GTP-ase signaling pathway.
residues in this loop can substantially reduce the binding affinity of hsp10 for hsp60 (4) (5) (6) . Folding of most proteins requires the interaction of hsp60 and hsp10, yet some proteins can be folded by hsp60 or hsp10 individually (4, 7, 8) . The preservation of denatured proteins under stress and the folding of newly synthesized proteins during the reperfusion period, following an ischemic insult, are believed to be a function of chaperonins. Evidence indicates that increased expression of hsp60 or hsp10 provides protection to myocytes submitted to a simulated ischemia/reoxygenation (SI/RO) insult and that simultaneous overexpression of hsp60 and hsp10 provides additional protection (9, 10) . We have previously reported that increased expression of hsp10 provides greater protection than increased expression of hsp60 during SI/RO in rat neonatal cardiac myocytes (NCM; 3, 10). Because hsp60 is the rate-limiting molecule in many folding studies (3), the protection afforded to myocytes by hsp10 during SI/RO is probably due to mitochondrial substrates specifically folded by hsp10 and/or to mechanisms independent of its mitochondrial chaperonin function.
The Ras, Raf, ERK signaling pathway has been studied in various cardiac myopathy models (11) (12) (13) . The role of the Ras signaling cascade, as well as its influence and contribution to cell death resulting from ischemia/reperfusion (I/R) insult, is the subject of debate. Our previous findings indicate that mechanisms involving cytoplasmic pathways may contribute to the protection afforded by hsp10. However, whether this protection involves the Ras signaling pathway or its constituents remains unexplored. To better understand the mechanism of protection from I/R injury afforded by hsp10, we generated a mutant hsp10 protein (P34H) that contained a proline to histidine substitution in the hsp10 mobile loop, which rendered the mutant incapable of interacting with hsp60. Using a SI/RO model, we examined the effects of overexpressing hsp10 and/or an hsp10 mutant in NCM, on components of the mitochondrial electron transport chain (ETC) and on components of the Ras signaling pathway. Our results indicate that overexpression of hsp10 leads to attenuation of Raf, ERK, and p90 Ribosomal kinase, which suggests a possible role for hsp10 in cardiac protection during SI/RO, independent of its chaperonin function.
MATERIALS AND METHODS

Cell culture and adenovirus construction
Rat NCM were harvested and cultured as previously described (9, 10) . HEK 293 cells were maintained as described in ATCC (CRL1573). Adenoviral vectors expressing hsp10 were generated as previously described (9, 10) . Briefly, cDNAs expressing wild-type human hsp10 or mutant hsp10(P34H) were inserted into the E1 region of the adenoviral plasmid pACCMVpLpASR -(a kind gift from Robert Gerard, University of Texas Southwestern Medical Center, Dallas), driven by the human cytomegalovirus immediate-early (CMV) promoter. Transfection of 293 cells with expression plasmids was performed by using Polyfect (Qiagen, Valencia, CA) according to the manufacture's protocol. Adenoviral vectors expressing RasN17 and RasV12 were generated as previously described (14) (15) (16) (17) (18) and were kind gifts from S. Chien (Dept. of Bioengineering, UCSD). Additionally, a recombinant adenoviral construct containing no insert (AdvSR-) was generated in parallel and used as a control. Viral constructs were plaque-purified and propagated in 293 cells, then cesium chloride-purified by ultracentrifugation.
Mutant hsp10(P34H) generation
The human hsp10 mutant was generated by using a polymerase chain reaction (PCR)-based approach. Briefly, two PCR reactions were performed by using the following primers and the human hsp10 cDNA as a template. In the first PCR reaction, Primers 1 and 2 were used with the human hsp10 cDNA as a template, and in the second, Primers 3 and 4 were used with the human hsp10 cDNA as a template. The two PCR products were ligated at the Rca1 site (underlined), which was introduced into the mutant hsp10 sequence. The full-length hsp10 wild-type and mutant proteins were expressed and purified by using a GST expression system (Amersham, Piscataway, NJ). Sequences encoding wild-type and mutant hsp10(P34H) were cloned into the pGEX-2TK plasmid (gift from S. Chien's Laboratory). Fusion proteins were expressed in E. coli BL21, purified by Glutathione Sepharose 4B, and cleaved by thrombin. Fusion protein quantification was determined by the Bradford method using bovine serum albumin as a standard (Biorad, Hercules, CA), and confirmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by Coomassie blue staining.
Mutant hsp10(P34H) functional analysis
Functional activities of wild-type and mutant hsp10(P34H) were measured by using an in vitro folding assay (19) with modifications. Briefly, mitochondrial malate dehydrogenase (MDH) was used as a substrate for hsp10-and hsp60-assisted folding. In a 100 µl refolding reaction, MDH (0.6 unit) was denatured for 90 min at 25°C in 4 µl of buffer C containing urea (4 M), HCl (75 mM), and ATP (25 mM). MDH was refolded by rapid mixing at 37 or 42°C with 96 µl of buffer C (without urea and ATP), recombinant hsp60 protein (Stressgen, Victoria, Canada), and either wild-type or mutant hsp10(P34H) fusion proteins (amount indicated in Fig. 2B ), in the presence of oxaloacetate (600 µM) and β-NADH (600 µM). The reestablishment of MDH activity was monitored by following the change in absorbance at 340 nm by a microplate spectrophotometer (Thermolab system).
The time-interval of each kinetic reading was 17 sec and was continued for 1 h or until stationary readings were reached. The rate of refolding by hsp60 and hsp10, defined as 100% in Fig. 2B (d) , was determined as the refolded MDH activity and was calculated by a linear regression of the readings in the last 3 min, which corresponded to the maximum rate before stationary readings were reached (R between -0.998 and -0.001). Using the same time period, the rate of refolding by other combinations of hsp60 and hsp10/mutant proteins was calculated (linear regression) and normalized to that of hsp60/hsp10 (d). The maximum amount of MDH refolded in our experiments was approximately 20% of the added denatured enzyme.
Simulated ischemia and reoxygenation (SI/RO) protocols
SI/RO was performed as previously described (9, 10) with minor modifications. Briefly, cells were kept in ischemic medium (glucose-free) Dulbecco's modified Eagle's medium (DMEM) and subjected to hypoxia by using the BBL GasPak system (Becton Dickinson, Cockeysville, MD) for various periods of time as indicated in the figure legends. Reoxygenation conditions were introduced by opening of the chamber, removal of ischemic media, and addition of DMEM with glucose for various periods of time as indicated in the figure legends. Sodium cyanide (NaCN) and hydrogen peroxide (H 2 O 2 ) treatments were performed with 5 mM NaCN or 200µM H 2 O 2 , respectively, for 4 h in an ischemic media supplemented with 2-deoxyglucose (20 mM). Control cells were maintained in DMEM with glucose.
Lactate dehydrogenase (LDH) release assay
LDH release was used as a determinant of cellular damage and death. LDH activity was measured at 340 nm using a kit (Sigma, St. Louis, MO). Cytoplasmic LDH release (cell death) was reported as the percentage of LDH activity present in the medium divided by the total enzyme activity (activity in medium + activity remaining in the cells). For NCM maintained in control conditions (48 h), the amount of enzyme released was 3-5% of the total enzyme activity. For myocytes (uninfected or infected with empty adenoviral vectors) subjected to SI/RO, the amount of enzyme released was 60-80% of the total enzyme activity (data not shown). The LDH release resulting from SI/RO, NaCN, or H 2 O 2 was determined as the difference in LDH release in treated cells and that of cells kept in the control conditions. Percent cell viability was assessed by trypan blue exclusion. A 0.2% trypan blue solution was added to the post-I/R cell suspension and viable (clear cytoplasm) and dead cells (blue-stained) counted by using a hemacytometer. Cell viability by trypan blue exclusion was correlated to LDH release, as shown in Fig. 1D , to give an indication as to the degree of cell death after I/R as it relates to LDH release, where 45% LDH release represents approximately 75% cell death.
Electron transport chain (ETC) function
HEK 293 cells transfected with plasmids overexpressing wild-type hsp10 or mutant hsp10(P34H) were treated with digitonin at a final concentration of 50 µg/ml for 5 min, according to the method of Hofhaus et al. (20) with modifications. Forty million cells were added to a polarographic chamber (YSI Inc., Yellow Springs, Ohio) with substrates and inhibitors added successively. Briefly, 20 µl of 1M glutamate and malate, 5 µl of rotenone (2 mM), 10 µl of 1 M succinate, 10 µl of 1 M malonate, 10 µl of 1 M glycerol 3-phosphate, 5 µl of 4 mM antimycin, 5 µl of 1 M N,N,N-tetramethyl-p-phenylenediamine (TMPD) and ascorbate, and finally 20 µl of 1 M NaCN were added to the chamber to measure the activity of each complex in the ETC. The Complex I activity was measured as the malate-/glutamate-dependent activity that was inhibited by rotenone, the Complex II [succinate dehydrogenase (SDH)] activity as the succinate-dependent respiration activity that was sensitive to the addition of malonate; the Complex III activity as the activity recovered by addition of glycerol-3-P and inhibited by antimycin A; and the Complex IV activity as the TMPD-/ascorbate-dependent activity that was inhibited by NaCN.
Protein analysis
Rat NCM infected with AdvSR-, AdvHsp10, or AdvmHsp10(P34H) were lysed by RIPA buffer (Santa Cruz Biotechnology, Santa Cruz, CA), and proteins separated by SDS-PAGE followed by Western blot. Blots were probed with primary antibodies against ERK, phosphorylated ERK, p90RSK, phosphorylated p90RSK, Raf-C, and phosphorylated Raf (New England Biolabs, Beverly, MA). Detection of signal was performed according to the NEN Renaissance ECL detection system according to the manufacturer's directions (NEN Life Sciences, Boston, MA). Blots were then exposed to film, and autoradiographic signals were assessed.
Statistics
Means and standard errors of the mean were calculated for all data sets. At least 3 independent experiments were performed (n=3) or are indicated in the text. In each experiment, triplicate samples were measured. ANOVA was performed in all comparisons, followed by post-hoc analysis (StatView, Cary, NC), except where a Student's t-test was appropriate (Fig. 1) . P values were determined by a Fisher's protected least significant difference (LSD) test, and a P<0.05 was considered significant.
RESULTS
Hsp10 overexpression protects against hypoxia/reoxygenation-induced damage
Rat NCM were infected with adenoviral vectors expressing wild-type hsp10 or an empty vector (AdvSR-), and LDH release was used as an assessment of cell death. Overexpression of hsp10 decreased H 2 O 2 induced cell death to 81% of the level in control virus infected myocytes (Fig. 1A,  P<0 .05). Hsp10 expression decreased NaCN-induced cell death to 64% of the level of control infected myocytes (Fig. 1B, P<0 .05) and decreased SI/RO-induced cell death to 45% of control (Fig. 1C, P<0 .05). Figure 1D correlates the percentage of LDH released to the percentage of cell death, where 45% LDH release represents approximately 75% cell death.
Hsp10 mobile loop modification causes temperature-sensitive impairment in MDH refolding
The sequence for the mutated hsp10(P34H) is shown in Fig. 2A . We examined the ability of this mutant protein to assist in the folding of proteins as shown in Fig. 2B . Denatured malate dehydrogenase (MDH) was used as the substrate for the folding assay, and folding dynamics were examined in the presence and/or absence of hsp60, wild-type hsp10, or mutant hsp10(P34H) proteins (Fig. 2B) . At 37°C, MDH was not refolded by hsp60 alone (a) but was folded with similar efficiency by either hsp10 or mutant hsp10(P34H) (b and c). Maximum MDH refolding occurred by inclusion of both hsp60, and wild-type hsp10, demonstrating folding cooperation by these chaperones (d). MDH refolding was less effective in the presence of both hsp60 and mutant hsp10(P34H) (e). Inclusion of both wild-type and mutant hsp10(P34H) with hsp60 decreased MDH refolding to a level significantly below that of hsp10 or mutant hsp10(P34H) alone (f). At 42°C, cooperative folding by mutant hsp10(P34H) and hsp60 was significantly reduced (e), yet folding by other combinations was not significantly changed.
ETC function in 293 cells overexpressing Hsp10 or mutant Hsp10(P34H)
Cells transfected with plasmids overexpressing wild-type or mutant hsp10(P34H) were subjected to polarographic analysis by measuring the rates at which the cells consumed oxygen in the presence of different substrates. NADH:ubiquinone oxidoreductase (Complex I) activity was determined as the malate/glutamate-dependent activity that was inhibited by rotenone. Increased hsp10 expression caused a significant increase in Complex I capacity compared with that of control cells (Fig 3A, P<0.05) . Overexpression of mutant hsp10(P34H) did not alter Complex I capacity (Fig. 3A) . We measured Complex II (SDH) capacity as the succinate-dependent respiratory activity that was sensitive to the addition of malonate. Mutant hsp10(P34H) significantly reduced the Complex II capacity, whereas wild-type hsp10 did not alter Complex II function (Fig. 3A, P<0.05) . Expression of wild-type or mutant hsp10(P34H) did not significantly alter the capacity of Complex III or IV (Fig. 3A) . Cells overexpressing hsp10 possessed greater Complex I and Complex II capacity compared with mutant hsp10(P34H) and control (AdvSR-) cells following SI/RO insult (Fig. 3B, P<0 .05 for both). No significant differences in Complex III and IV activities were observed following SI/RO (Fig. 3B) .
Overexpression of mutant Hsp10(P34H) decreases protection against SI/RO
Rat NCM were infected with viruses overexpressing hsp10, mutant hsp10(P34H), or an empty control virus (AdvSR-) and subjected to SI/RO. Cell death by SI/RO in cells infected with the control virus was taken as 100%, and overexpression of mutant hsp10(P34H) increased cell death to 120% (Fig. 4, P<0.05 ). NCM infected with an adenovirus encoding hsp10 decreased cell death (Fig. 4, P<0.05) . Combination of mutant hsp10(P34H) and wild-type hsp10 abolished the protection afforded by hsp10 overexpression (Fig. 4, P<0.05 ).
Attenuation of the Ras, Raf, ERK, p90RSK signaling pathway with Hsp10 overexpression
We determined the potential association of hsp10 and subsequent activity of the Ras pathway during SI/RO insult. Adenoviral vectors expressing a constitutively active form of Ras (AdvRasV12) and a dominant-negative mutant form of Ras (AdvRasN17) were used as models to determine whether Ras activation or inactivation resulted in myocyte preservation after SI/RO. Constitutively activating Ras (AdvRasV12) in myocytes for 2 days resulted in an increase in cell number and cell size (data not shown). After SI/RO, cell death was increased in myocytes infected with AdvRasV12 (124% vs. 100%) compared with control virus-infected myocytes (Fig. 5,  P<0 .05). Overexpressing a dominant-negative mutant of Ras (AdvRasN17) in myocytes resulted in fewer cells after 2 days of culture (data not shown). These myocytes, however, were better preserved (56% vs. 100%) after the same SI/RO treatment compared with control-infected myocytes, as indicated by a decrease in cell death (Fig. 5, P<0. 
05).
To test whether wild-type hsp10 or mutant hsp10(P34H) could modulate the protective or detrimental effects by either RasN17 or RasV12, respectively, we coinfected myocytes and subjected them to SI/RO. Co-expression of wild-type hsp10 and RasN17 attenuated cell death compared with RasN17 alone (Fig. 5, P<0.05) . Further, co-expression of mutant hsp10(P34H) with RasN17 abolished this effect (Fig. 5, P<0.05) . In contrast, overexpression with either wild-type hsp10 or mutant hsp10(P34H) in addition to RasV12 did not result in significant differences in cell death compared with RasV12 alone.
Hsp10 overexpression attenuates phosphorylation of Raf, ERK, and P90ribosomal kinase
To determine whether hsp10 overexpression results in altered phosphorylation of proteins in the Ras pathway, we performed Western blots on myocytes infected with hsp10 or an empty control virus (AdvSR-) and subjected them to SI/RO. Using antibodies against phosphorylated Raf, RafC, phosphorylated ERK, ERK1/2, and phosphorylated p90ribosomal kinase (p90RSK), we observed decreases in the phosphorylation level of Raf, ERK, and p90RSK in myocytes overexpressing hsp10, before and after SI/RO (Fig. 6A) . Because P90RSK was a downstream protein of ERK, we compared the effect of overexpression of hsp10, RasV12, or RasN17 on p90RSK phosphorylation. Hsp10 overexpression led to a slight decrease in the amount of phosphorylated p90RSK compared with RasV12 and RasN17 overexpression, which led to a strong increase and decrease of p90RSK phosphorylation, respectively (Fig. 6B) .
DISCUSSION
Hsp's are responsible for folding newly synthesized proteins and proteins that become denatured during conditions of cellular stress. The latter function is particularly important for cells presented with ischemic insult (21) . Mitochondrial chaperonins play a crucial role in preserving cardiac viability during myocardial ischemia due to several factors. First, most mitochondrial proteins are nuclear-encoded and must be folded by matrix chaperonins such as hsp60 and hsp10 after import into the mitochondria. Second, the preservation of oxidative phosphorylation, ETC complex function, and ATP generation are essential to cardiac contractile function, and as such, mitochondrial proteins involved in these processes may be compromised during myocardial ischemic events, decreasing functional recovery, and triggering the apoptotic program. We have demonstrated that increased expression of hsp10 and/or hsp60 decreases apoptosis in myocytes after SI/RO (10) . Additionally, we observed benefit from increased hsp10 expression independent of its mitochondrial chaperonin function. As a result, we investigated alternative protective mechanisms associated with hsp10.
Our SI/RO protocol consists of a hypoxic period and a reoxygenation period that mimics the myocardial ischemia and reperfusion that occurs when an occluded coronary artery is opened. The reperfusion or reoxygenation phase has been linked to generation of reactive oxygen species (ROS) that contribute to cellular damage (22, 23) . We determined whether increased expression of hsp10 protects against hypoxia and reoxygenation-related injuries by examining three separate models; H 2 O 2 treatment, metabolic inhibition of oxidative phosphorylation (NaCN) and recovery, and simulated ischemia and reoxygenation (SI/RO). Our results indicate that increased hsp10 expression provides protection against both hypoxia (metabolic ischemia or simulated ischemia) and reoxygenation insults. Further, hsp10 is most protective against SI/RO, followed by metabolic inhibition of oxidative phosphorylation by utilization of sodium cyanide (NaCN), and finally, least protective against H 2 O 2 treatment that lacks an ischemic period. It remains to be explored, as to whether hsp10 is protective during the ischemia period.
The structure and function of the hsp10 mobile loop has been studied extensively (6, 19, 24, 25) . Three-dimensional structural analysis of the 18 amino acids of the mobile loop of hsp10 indicates that the region interacting with hsp60 may be critical for the stability of hsp10-hsp60 complexes and thus crucial for substrate folding. Mutations in the mobile loop may result in either stronger binding kinetics (increased affinity) by decreasing flexibility (disfavor mobility), or weaker binding kinetics (increased flexibility) by impeding the loop conformation (increased entropy) (6, 21, 22) . The proline 34 residue in the mobile loop is particularly important, and mutations at this residue reduce the conformational dynamics (entropy), and decrease the affinity of yeast hsp10 (P33S, P33H) for GroEL (6) . Using this information, we engineered a mutant hsp10(P34H) protein, in which proline 34 is replaced by histidine, creating a temperature-sensitive mammalian mutant protein, similar to the yeast P33H strains. By using MDH as a substrate, mutant hsp10(P34H) exhibits functional impairment in folding mitochondrial substrates at 37°C, although this attenuation is more evident at elevated temperatures. Our data suggest that a proline to histidine mutation in the mobile loop of hsp10 compromises binding with hsp60 and reduces this synergy. The detrimental effects of mutant hsp10(P34H) overexpression may be twofold. First, folding of substrates that require both hsp60 and hsp10, cooperatively, is inhibited by mutant hsp10(P34H); second, folding of substrates, such as MDH that require only endogenous hsp10, are also inhibited by mutant hsp10(P34H) (34) . Overexpression of mutant hsp10(P34H) resulted in greater myocyte death after SI/RO compared with wild-type hsp10, which may be related to a defect in folding mitochondrial matrix and ETC proteins. To test this hypothesis, activities of the individual components of the mitochondrial ETC chain were measured by polarographic analysis. Overexpression of wild-type hsp10 increased Complex I capacity. In contrast, mutant hsp10(P34H) caused a reduction in Complex II (SDH) capacity. Following SI/RO, all ETC complex activities were decreased, which is probably due to overall cellular damage. Further, overexpression of wild-type hsp10 specifically increased both Complex I and Complex II capacities following SI/RO, whereas mutant hsp10(P34H) overexpression had no significant effect. These results are interesting for several reasons. Complex I consists of the most enzyme subunits and is usually considered the rate-limiting step in State 3 respiration (20) . The beneficial effect of hsp10 overexpression during ischemic injury may be related to increased efficiency of respiration by increased Complex I capacity, due in part to preservation of Complex I constituents. Further, the decrease in SDH capacity by mutant hsp10(P34H) in the control condition and the increase in SDH capacity during SI/RO suggests that either expression of SDH or assembly of SDH was affected. The inconsistent results by hsp10 and mutant hsp10(P34H) may also suggest that multiple and different matrix proteins are effected by hsp10 and by mutant hsp10(P34H) due to substrate-specific dependence on the cooperative folding by hsp60 and hsp10.
The involvement of the Ras signaling cascade in cardiac myopathy has been discussed extensively in the context of dilated cardiac myopathy, and the activation of Ras leads to hypertrophy and heart failure. Although activation of downstream members of the Ras cascade, such as ERK, may be cytoprotective in I/R injury, other members of the MAP kinase family, such as JNK or p38MAP kinase, have roles in both pro-death and pro-survival actions during I/R and other ROS-related injuries (12, 13, 26) . Due to differences in models, cell types, methods, protocols, and reagents, conflicting results are not uncommon among studies, and conclusions regarding myocyte benefit resulting from activation of members of the Ras cascade are controversial. Our finding that Ras activation increased NCM size is in agreement with the hypertrophic role of Ras. Constitutive activation of Ras resulted in hypertrophy and in higher ATP demand, metabolites, and oxygen due to higher metabolism by the mitotic stimulation of Ras in myocytes. Subjecting myocytes to SI/RO resulted in more severe damage (11) . In contrast, myocyte growth was inhibited by overexpressing dominantly negative RasN17 such that there was less demand for ATP and oxygen, which was similar to the effect of preconditioning. As such, these myocytes were better preserved during SI/RO. The beneficial effects observed with hsp10 overexpression and the detrimental effects observed with mutant hsp10(P34H) overexpression during SI/RO were evident in myocytes with Ras inactivation but not in myocytes with Ras activation. These results suggest that Ras inactivation may be required for the beneficial effects of hsp10. The mechanism for hsp10 protection is hypothesized in Figure 7 , where Ras inactivation attenuates myocyte death during SI/RO (cell protection). Hsp10 and mutant hsp10(P34H) both require the deactivation of the Ras pathway to exercise their biological effects. Ras-independent mechanisms also exist because additional benefits and damage were found in cells expressing hsp10 or mutant hsp10(P34H) in addition to RasN17. The protein folding and mitochondrial ETC results that we have observed are probably due to a Ras-independent mechanism. It should be noted that overexpression of hsp10 did not necessarily result in strong Ras inactivation, although the latter is required to observe the beneficial effects from hsp10.
We examined the phosphorylation state (presumably the activity) of Raf, ERK, and p90RSK, which all belong to one of the many cascades that can be activated by Ras. Our data indicate that hsp10 leads to down-regulation of this pathway in control and SI myocytes but that the level of deactivation is not as significant as that by RasN17. The potential effecter of this cascade is the sodium proton exchanger (NHE), a substrate of p90RSK. Activation of NHE and subsequent calcium overload are implicated as major determinants of myocyte death in I/R injury. It has been proposed that inhibition of NHE activity is a potential therapeutic for treating ischemic cardiomyopathy (27) (28) (29) (30) (31) (32) (33) , and our findings are in agreement with this strategy. The mechanism of inactivation of the Ras cascade by hsp10, such as the physical association of these molecules with hsp10, was also explored, and we did not find evidence of direct association of hsp10 with NHE, ERK, or Raf (data not shown).
In summary, our results indicate that increased hsp10 expression protects myocytes against SI/RO, metabolic ischemia (NaCN), and H 2 O 2 injury. Mutation of the mobile loop of hsp10 impairs the chaperonin function and abolishes the cardiac protection by hsp10. Protection by hsp10 involves the down-regulation of the Ras pathway and also a Ras-independent mechanism that may be related to preservation of the mitochondrial ETC, particularly Complex I. Our data suggest that a novel mechanism involving chaperonin function, oxidative phosphorylation, and cytoplasmic Ras signaling may contribute to the beneficial effects afforded by hsp10 during SI/RO in myocytes. sodium cyanide (NaCN), and (C) simulated ischemia and reoxygenation (SI/RO). NCM were infected with adenoviral vectors overexpressing hsp10 or a control virus (AdvSR-). Forty-eight hours post-infection, myocytes were challenged with H 2 O 2 (200 uM) for 24 h, NaCN (5 mM) for 4 h followed by reperfusion with normal medium for 24 h, or SI/RO for 6 h followed by reoxygenation for 24 h. Cell death in control virus-infected cells was designated as 100%. *P < 0.05, n=3. D) Percent cell viability correlated to LDH release after I/R in NCM. Cell viability was assessed by trypan blue exclusion post-I/R where viable (clear cytoplasm) and dead (blue-stained) cells were counted by using a hemacytometer. n = 3 for all groups. In vitro protein-folding assay for hsp10 and mutant hsp10(P34H). The reestablishment of MDH activity was monitored at 37 or 42°C and micrograms of hsp60, hsp10, and mutant hsp10(P34H) added are indicated. The refolding rate under a given temperature from samples containing both hsp60 and hsp10 was taken as 100% (d) and used to normalize the rates from other hsp60-hsp10 combinations. For the 37°C group, *P < 0.05 compared with (d), n = 8. Similarly, † P < 0.05 for the 42°C group, n = 6. # P<0.05, for significant reduction vs. normalized rates obtained at 42°C from that obtained at 37°C. Myocytes were infected for 48 h with AdvSR-, AdvHsp10, AdvmHsp10(P34H), or AdvHsp10 and AdvmHsp10(P34H) and were challenged to SI/RO for 6 h followed by reoxygenation for 24 h. Cell death in control virus infected cells was designated as 100%. *P < 0.05, compared with AdvSR-; † P < 0.05, compared with Hsp10, n = 3 for all groups. infected for 48 h with AdvSR-, AdvRasN17, and AdvHsp10, AdvRasN17, and AdvmHsp10(P34H), AdvRas V12, AdvRasV12 and AdvHsp10, or AdvRasV12 and AdvmHsp10(P34H) and challenged to SI/RO for 6 h followed by reoxygenation for 24 h. Cell death after SI/RO from AdvSR-infected cells was designated as 100%. *P < 0.05, compared with AdvSR-. † P < 0.05, compared with cell death after SI/RO in AdvRas-N17 infected cells. n = 3 for all groups. infected with adenoviral vectors overexpressing hsp10 or a control virus (AdvSR-). Forty-eight hours post-infection, myocytes were challenged to SI/RO for 6 h, followed by reoxygenation for 24 h. C: Control condition. SI: Myocytes subjected to simulated ischemia. B) Western blots for the phosphorylation status of p90RSK. Myocytes were infected for 48 h with adenoviral vectors expressing control virus (AdvSR-), Advhsp10, advRasV12, or AdvRasN17 and were challenged to SI/RO for 6 h followed by reoxygenation for 24 h. Relative band intensities of pP90RSK are indicated, and the first lane is arbitrarily taken as 1. 
